Dronabinol
- Generic Name
- Dronabinol
- Brand Names
- Marinol, Sativex, Syndros
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 1972-08-3
- Unique Ingredient Identifier
- 7J8897W37S
- Background
Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...
- Indication
Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
- Associated Conditions
- Anorexia, Chemotherapy-Induced Nausea and Vomiting
- Associated Therapies
- -
Ananda Developments Epilepsy Trials
Ananda Developments' MRX2 and MRX2T cannabinoid medicines will be used in two NIHR/NHS-funded Phase IIIa epilepsy trials involving up to 500 patients, conducted by UCL and GOSH. The trials aim to test the safety and efficacy of CBD and CBD+THC formulations for treatment-resistant epilepsy, with potential for regulatory approval if successful.
ANALYSIS: Cannabis Rescheduling Unlocks Pharma's Next Frontier
Cannabis's move to Schedule III of the Controlled Substances Act will remove barriers for pharmaceutical companies to develop cannabis-based drugs, unlocking a $2 trillion market. This shift will favor pharma companies over state-level cannabis businesses, as the latter lack the resources for FDA approval. Pharmaceutical companies are already patenting solutions to the 'whole-plant' problem, positioning them to dominate the federally regulated market for cannabis-based prescription drugs.
NJEDA Board Approves NJ Innovation Evergreen Fund Investment into Princeton-Based
NJEDA Board approves NJIEF's fourth investment, $400,000 into Princeton's RICOVR Healthcare, developing a rapid THC diagnostic test. NJIEF aims to boost NJ's economy by supporting high-growth startups. RICOVR's XALIVA device targets fair workplace cannabis testing, with potential expansion into other health markets.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath